RSPO2 and pachyonychia congenita: Based on an aggregate of 16 PC datasets consisting of 1051 tumors, RSPO2 amplifications (n = 104) were overrepresented in metastatic samples relative to primary tumor samples (54% vs. 28%, respectively) (Figure 2C).